Overview
GALT market data
Price History
No market bars yet for GALT. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GALT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 14, 2026, 4:38 PM
Top 3 Health Care Stocks That May Keep You Up At Night In JuneBenzinga · Jun 30, 2026, 1:00 PM
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price TargetBenzinga · Jun 23, 2026, 4:40 PM
Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal HypertensionBenzinga · Jun 23, 2026, 12:15 PM
8-K filing — GALECTIN THERAPEUTICS INC (GALT)SEC EDGAR · Jun 23, 2026, 11:51 AM
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisGlobenewswire Inc · May 27, 2026, 12:15 PM
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) EstimateBenzinga · May 15, 2026, 12:20 PM
Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluating Belapectin In Patients With MASH Cirrhosis And Portal Hypertension In AASLD Flagship Journal HepatologyBenzinga · May 11, 2026, 12:07 PM